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Retroperitoneal sarcomas are rare and treatment should optimally be centralized. Despite successful centralization with 90%
of the patients referred prior to surgery, delays occur, which led us to assess lead times in a population-based series. Method.
Patients diagnosed with retroperitoneal sarcoma in the southern Sweden health care region 2003–2009 were eligible for the study.
Data on referrals and diagnostic investigations were collected from clinical ﬁles from primary health care, local hospitals, and
from the sarcoma centre. Lead times were divided into patient delays and health care delays caused by primary health care, local
hospitals, or procedures at the sarcoma centre. Results. Complete data were available from 33 patients and demonstrated a median
patient delay of 23days (0–17months) and median health care delay of 94days (1–40months) with delays of median 15days at the
general practitioner, 36days at local hospitals, and 55days at the sarcoma centre. Conclusion. Centralization per se is not suﬃcient
for optimized and eﬃcient management. Our ﬁndings suggest that delays can be minimized by direct referral of patients from
primary health care to sarcoma centers and indicate that development of coordinated diagnostic packages could shorten delays at
the sarcoma centre.
1.Introduction
Retroperitoneal sarcomas represent 0.1% of all malignancies
and are often clinically challenging due to anatomical
proximity to vital structures and a considerable risk for local
recurrence [1]. The rarity, complex diagnostics, and surgical
challenges imply that these tumors should be managed by
experienced sarcoma teams. Centralized treatment per se
may not be suﬃcient since delays that may allow tumor
progression, complicate surgery, increase the risk of local
recurrence, and cause unnecessary worry for patients are
experienced at general practitioners and local hospitals as
well as at sarcoma centers [2–6]. Delays have been linked
to adverse outcome in several tumor types, including breast
cancer, colorectal cancer, urothelial cancer, and esophageal
cancer [7–10]. Benchmarks for timely management have not
been deﬁned in retroperitoneal sarcoma, but large tumor
size represents an adverse prognostic factor, which strongly
argues for eﬃcient management. Detailed understanding of
the causes of delays is needed for optimized management,
which led us to identify diagnostic lead times related to
the patient, general practitioners, and procedures at local
hospitals and at the sarcoma centre in a population-based
series of retroperitoneal sarcoma patients.
2.MaterialsandMethods
Primary, histologically veriﬁed retroperitoneal sarcoma was,
in the southern Sweden health care region (1.5 million
inhabitants), diagnosed in 39 patients between 2003 and
2009. Complete data were available from 33 patients. All
relevant medical records from general practitioners, local
hospitals and the sarcoma centre were collected. Patient’s2 Sarcoma
Table 1: Summary of clinicopathologic characteristics.
Characteristics N (%)
Sex (male:female) 17:16
Age, mean (range) 66 (21–87)
Tumor size, cm, mean (range) 21 (4–60)
Histopathologic type
Liposarcoma 13 (40)
Leiomyosarcoma 8 (24)
Spindle cell sarcoma 4 (12)
Inﬂammatory myoﬁbroblastic sarcoma 1 (3)
GIST 1 (3)
Carcinosarcoma 1 (3)
Atypical solitary ﬁbrous tumor 1 (3)
NOS 4 (12)
Malignancy grade
Low 9 (27)
Intermediate 1 (3)
High 19 (58)
NOS 4 (12)
GIST: gastrointestinal stromal cell tumor.
NOS: not otherwise speciﬁed.
delay was deﬁned as the time from onset of self-reported
symptoms to the ﬁrst visit to a medical professional, which
could be a general practitioner or a specialist. Health care
delay was deﬁned as the time from the ﬁrst visit to the start
of treatment, which was in most cases surgery. Hereunder,
lead times were speciﬁed to occur in primary health care
(from the ﬁrst visit to a general practitioner until referral
to a local hospital or sarcoma centre), at local hospitals
(from the ﬁrst visit until the start of treatment or referral
to the sarcoma centre) or in the sarcoma centre (from the
ﬁrst visit until start of treatment). Pathology lead time was
deﬁned as the time from referral for cytology/biopsy until
conﬁrmed malignancy. Radiology lead time was deﬁned as
the time from referral for the ﬁrst investigation to the result
of the ﬁnal investigation. All lead times were expressed as
median times in order to minimize the impact of skewed
distributions. According to Swedish health care regulations,
the study represents a quality control project, for which
ethical permission is not required.
3. Results
Complete data were available from 33 patients (Table 1). The
mean age at diagnosis was 66 (21–87) years, and the study
included 17 men. Liposarcoma and leiomyosarcoma were
the predominant histopathological subtypes. The majority
(n = 19) of the tumors were high grade and the mean
tumor size was 21 (4–60)cm. Median and individual delays
are presented in Figures 1 and 2. The median lead time from
onset of self-reported symptoms to the ﬁrst medical visit
was 23 days (0–17 months). Though 15 patients consulted a
medical professional within 1 month of onset of symptoms,
patient’s delay was the predominant in 12/33 cases. The
Onset of symptoms
Patient delay
23 (0–524) days
General practitioner
General practitioner delay
15 (0–244) days
Sarcoma centre
Sarcoma centre delay
55 (1–483) days
N = 30
Start treatment
Local hospital
Local hospital delay
36 (2–1123) days
Figure 1: Overview of the diﬀerent median lead times.
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Figure 2: Bar chart demonstrating individual patients’ lead times
(one outlier with a 3-year local hospital delay was omitted for
reasons of illustration).
most common symptoms (n = 14) were pain or abdominal
discomfort whereas 4 tumors were incidentally diagnosed
at surgery or radiologic investigations for other causes. The
totalhealthcareleadtimewasmedian94days(1–40months)
and consisted of a general practitioner’s lead time of median
15 days (0–8 months), a local hospital lead time of 36 days
(0–37 months), and a sarcoma centre lead time of 55 days
(1–16 months). The longest delays were caused by erroneous
primary diagnosis (7, 16, and 40 months) and comorbidity
that required complimentary medical procedures prior to
surgery (5, 8, and 19 months). Among the 17 patients who
consulted a general practitioner, 11 were referred within 1
month of the ﬁrst visit and 6 were referred directly to the
sarcoma centre. From local hospitals, 11/23 patients were
referredtothesarcomacentrewithin1month,whichimplies
that half of the patients spent more than a month at this
stage. The sarcoma centre lead time of median 55 days
represented the longest delay in 12/33 patients.
The diagnostic delays were divided into pathology and
radiology lead times (Figure 3). In 25 patients, a ﬁne
needle aspiration cytology and/or core needle biopsy was
performed, 14 of which were performed at the sarcomaSarcoma 3
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Figure 3: Box-plot demonstrating the radiology, pathology, and
surgery lead times at the sarcoma centre. Outliers are marked by
•.
centre. The pathology lead time was median 22 days (0–4
months) with some of the longest delays caused by inconclu-
sive results from cytology/histopathology. Repeated needle
biopsies were required in 5 patients, and 11 patients were
operated on without a histologically conﬁrmed diagnosis.
Radiology lead time was median 36 days (0–8 months) and
the investigations included abdominal CT scans in all but
one patients, complemented with CT scans of the thorax
and renography in most patients. The delay from completed
diagnostics to surgery was median 13 (1–57) days.
4. Discussion
Management of retroperitoneal sarcomas requires a multi-
disciplinary approach with contributions from radiologists,
pathologists, surgeons, and oncologists. Though primary
surgery at a sarcoma centre is beneﬁcial, eﬃcient diagnostics
is central. In southern Sweden, centralized treatment has
been promoted since a decade with 90% of the patients
currently referred to the sarcoma centre before surgery. In
order to characterize delays and causes hereof, we assessed
lead times in our population-based cohort. The median
patient’s delay was only 3 weeks, though considerable longer
delays occurred in some cases and indeed represented the
predominant delay in almost half of the patients (Figure 2).
It should, however, be kept in mind that these data are based
on self-reported symptoms and thus prone to bias compared
totheotherleadtimes,whicharebasedondocumenteddates
of referral. No comparison can be made to published delays
forretroperitonealsarcoma,butinsoft-tissuesarcomas,con-
siderable delays have been reported. Brouns et al. reported
median patient’s delays of 2 months in more than half of the
patients and of at least 6 months in 20% of patients [11].
Clark and Thomas reported lead times of median 12 months
inreferringsarcomapatientsfromgeneralpractitioners[12].
We found a median general practitioners’ delay of 16 days,
which indeed represents the shortest health care lead time.
Considering the rarity of retroperitoneal sarcomas, these
prompt reactions to suspected malignancy are impressive.
Our data demonstrate that the time is lost at the
subsequent step for patients that are primarily referred to a
local hospital. The median lead time from the local hospital
to the sarcoma centre was 5 weeks, and in several cases
investigations originally performed at the local hospital were
repeated at the sarcoma centre. This observation strongly
suggest that patients with suspected retroperitoneal sarcoma
should be directly referred to the sarcoma centre in order to
a v o i du n n e c e s s a r yp r o c e d u r e sa n dr e d u c el e a dt i m e s .
A series of investigations are typically needed in the
diagnostic workup and surgical planning of retroperitoneal
sarcoma and treatment decisions are made at multidisci-
plinary conferences. Against this background, it is not sur-
prising that the sarcoma centre lead time of median 8 weeks
was predominant. Additional morphological investigations
needed to reach a pathological diagnosis and requests for
complimentary imaging were identiﬁed as the major causes
of delay (Figure 3). Radiology delays were the predominant
with median delays exceeding 5 weeks in half of the cases.
Separate requests for diﬀerent examinations rather than
coordinated examinations likely contributed to the delays.
Due to limited resources at the sarcoma centre, a signiﬁcant
number of radiology investigations were also performed
at local hospitals, which contributed to longer lead times,
since the results of the investigations were not immediately
available to the surgeons at the sarcoma centre. This leads
us to suggest that retroperitoneal sarcoma radiology pack-
ages could be deﬁned to achieve eﬃcient and coordinated
radiologic investigations and hereby reduce lead times. The
pathology lead time of median 3 weeks leaves room for
improvement. We suggest that cytology specimens from
ﬁne needle examinations should be immediately evaluated.
Hereby, representative material can be directly ensured
and direct resampling ordered when necessary. Finally, the
median lead time of 2 weeks from complete diagnostic
workup until surgery is considered acceptable against the
background of coordinated eﬀorts from oncological sur-
geons.
Studies that have addressed the diagnostic delays in other
less common tumor types; that is, esophageal cancer and
cancer of the urinary tract have reached results similar to
ours. Esophageal cancer also requires extensive diagnostic
workup followed by complex surgery when possible. Groten-
huisetal.showedamedianhospitaldelayof7weeksfromthe
endoscopy at which a diagnostic biopsy was obtained until
surgery and median 2 weeks from the treatment decision
at a multidisciplinary conference until surgery [10]. The
authors could also demonstrate that rapid management was
associated with favorable outcome as regards both morbidity
and mortality. Holm¨ ang and Johansson analyzed diagnostic
and treatment delays in patients with upper urothelial cancer
with a median delay from urography to surgery of 3–8
w e e k sw i t hc o n s i d e r a b l ed i ﬀerences in delay and tumor
stage between diﬀerent hospitals [9]. They suggest that large
tumors lead to more rapid workup and earlier surgery. The
rarity and variable clinical course of retroperitoneal sarcoma
precludes analysis of outcome, but interestingly, some of
the longest doctor’s delays occurred in patients with large
tumors.4 Sarcoma
We conclude that a substantial number of patients in this
population-basedretroperitonealsarcomacohortexperience
considerable diagnostic delays. General practitioners’ delays
were acceptable, local hospital delays should be possible to
minimize, and sarcoma center delays could be shortened
through improved coordination. Our data point to three
possible improvements. Patients with suspected retroperi-
toneal sarcomas should be directly referred to sarcoma
centers to reduce lead times at local hospitals. At the sarcoma
centre, radiologic and pathologic investigations should be
coordinated, for example, through predeﬁned radiology
packages and prioritized evaluation of cytology/pathology
specimens. Finally, lead times should be prospectively reg-
istered in order to map bottle necks in diﬀerent systems
and evaluate the eﬀect of altered routines for diagnostic
workup. Such data would also allow for establishment of
clinical diagnostic guidelines and limits for timely care of
retroperitoneal sarcoma.
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